Immune checkpoint inhibitors (ICIs), including antibodies against programmed cell death-1 (PD-1) and PD-1 ligand-1 (PD-L1), induce their anti-tumor effects by improving the function of immune cells11. This evidence concerns the gene CD274 and neoplasm.